Aspirus seeks participants for worldwide cardiovascular disease clinical trial
Metro Wire Staff
Aspirus Research Institute is seeking participants for a clinical study that has the potential to improve future treatment options for people living with cardiovascular disease.
If you have had a heart attack or stroke, or have poor circulation, you may be eligible for the study.
The REDEFINE 3 Study will look at the safety and potential benefits of cagrilintide and semaglutide (CagriSema) on cardiovascular events, like heart attack and stroke, in people living with cardiovascular disease.
During the study, researchers will track cardiovascular events (heart attack, stroke, or heart-related deaths) as well as changes in body weight and A1C.
Participants may qualify if they:
- Had a stroke, heart attack, or have poor circulation (peripheral artery disease)
- Are 55 years of age or older
- Are considered overweight or living with obesity (BMI>25)
- Have type 2 diabetes
- Can have chronic kidney disease
- Can attend regular clinic visits and receive phone calls for up to four-and-a-half years, depending on study start date
The study sponsor, Novo Nordisk, expects the study to last up to four-and-a-half years and enroll 7,000 participants in the United States and across the world.
There are no costs associated with participation and patients are reimbursed for all study-related visits.
For more information about the REDEFINE 3 study, please contact visit aspirus.org/redefine3 or call Aspirus Research Institute at 715.847.2273.
